Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)
NCT04452500
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PTSD
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- January 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Tuscaloosa VA Medical Center, Tuscaloosa, AL · Tuscaloosa, AL
California · 1
- San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.